Recent advances in psychedelic research have renewed interest in their therapeutic potential for psychiatric disorders characterized by cognitive and behavioral rigidity. This review examines the rationale for using serotonergic psychedelics-particularly 5-HT2A receptor agonists such as psilocybin-in the treatment of eating disorders (EDs), including anorexi...
Unknown journal
2025-08-20
Bilenker D, Avena NM.
Europe PMC Published
psilocybin Eating DisordersNeuroplasticityBrain ImagingMechanism of ActionReceptor PharmacologyAgingClinical TrialReview ArticleAnimal StudySafety Clinical Trial
PurposeRecent years have witnessed a renewed interest in research exploring the therapeutic potential of classic psychedelics, such as psilocybin and lysergic acid diethylamide (LSD) in the treatment of mental disorders. However, our knowledge of the epidemiology of their use, factors associated with their recreational consumption, and attitudes toward these...
Unknown journal
2025-08-20
Holas P, Kamińska J.
Europe PMC Published
psilocybin AddictionObservational Study Observational Study
Psilocybin, a serotonergic compound that produces psychedelic effects primarily through activation of the 5-HT2A receptor, has shown promise in treating neuropsychiatric conditions, including obsessive-compulsive disorder (OCD). However, the effects of chronic psilocybin administration on gut function, microbiota, and behavioural phenotypes remain understudi...
Unknown journal
2025-08-20
Gattuso JJ, Kong G, Bezcioglu B, Lu D, Ekwudo MN, Wilson C, Gubert C, Hannan AJ, Renoir T.
Europe PMC Published
psilocybin DepressionAnxietyOCDMechanism of ActionReceptor PharmacologyAnimal StudyMicrobiome Animal Study AnimalsMice
Unknown journal
2025-08-19
Koenig HG.
Europe PMC Published
psilocybin DepressionSafety Other
Abstract Background Psychedelic-assisted therapy (PAT) is gaining attention as a potential treatment for cancer-related psychosocial symptoms. While growing evidence highlights its promise, little is known about how different stakeholder groups perceive its use in oncology and palliative care. Objectives This study aimed to assess stakeholder-specific perspe...
Research Square
2025-08-18
Schuman HD, Deleemans JM, Nguyen T, Savard C, Mina R, Carlson LE.
Europe PMC PREPRINT (not peer reviewed)
psilocybin End-of-Life DistressObservational StudyCancer PatientsSafety Observational Study
Through its widespread reciprocal connections with the cerebral cortex, the claustrum is implicated in sleep and waking cortical network states. Yet, basic knowledge of neuromodulation in this structure is lacking. The claustrum is richly innervated by serotonergic fibers, expresses serotonin receptors, and is suggested to play a role in the ability of psilo...
Unknown journal
2025-08-18
Madden MB, Schaefgen C, Vedak B, Kwon J, Pedra KSD, Sheats SH, Puche AC, Wolff SBE, Mathur BN.
Europe PMC Published
psilocybinpsilocin NeuroplasticityMechanism of ActionReceptor PharmacologyAnimal Study Animal Study Gyrus CinguliCerebral Cortex
Psychedelics, particularly psilocybin, have garnered significant attention as potential therapeutic tools for treating substance use disorders (SUDs), such as those related to alcohol, nicotine, heroin (an opioid), or cocaine. Traditional treatments often fall short, leading to high relapse rates and an urgent need for innovative approaches. This article exp...
Unknown journal
2025-08-18
Li Y, Li H, Wang H, Wang X.
Europe PMC Published
psilocybin AddictionNeuroplasticityClinical TrialSafety Clinical Trial AnimalsHumans
Existential and spiritual suffering are frequently reported by individuals facing serious illnesses, particularly at the end of life, and are associated with diminished quality of life, increased psychological distress, and requests for hastened death. While Palliative Care (PC) aims to provide holistic support, existing therapeutic options often fail to ade...
Unknown journal
2025-08-17
Garcia ACM, Maia LO.
Europe PMC Published
psilocybin End-of-Life DistressMechanism of ActionSpiritualityReview Article Review Article HumansHallucinogens
The stresses of the Coronavirus Disease of 2019 (COVID-19) pandemic highlighted the burden of psychiatric disorders within the pediatric population, revealing a pre-existing need for rapid-onset therapies that have since driven efforts to expand effective therapeutic interventions. In this narrative review, we utilized the Preferred Reporting Items for Syste...
Unknown journal
2025-08-17
Hughes B, Mirza S, Ponamala M, Sagaser J, Paredes R, Hematillake N, Tailor C, Khan R, Pemminati S.
Europe PMC Published
psilocybin DepressionAnxietyPTSDNeuroplasticityMechanism of ActionReceptor PharmacologyEmotional ProcessingMeta-AnalysisSystematic ReviewReview ArticleAdolescentsTreatment-Resistant Depression Meta-Analysis
Depression is a prevalent and heterogeneous disorder with significant personal and social consequences. The rise of treatment-resistant depression (TRD) challenges traditional approaches and underscores the need for a broader neurobiological perspective. When monoaminergic modulation proves insufficient, clinical guidelines increasingly turn to non-monoamine...
Unknown journal
2025-08-15
Rosa I, Padula LP, Semeraro F, Marrangone C, Inserra A, De Risio L, Boffa M, Zoratto F, Borgi M, Guidotti R, Lorenzo GD, D'Addario C, Pettorruso M, Martinotti G.
Europe PMC Published
psilocybin DepressionMechanism of ActionReceptor PharmacologyReview ArticleAnimal StudyTreatment-Resistant Depression Review Article AnimalsHumans
Novel phenalkylamines and tryptamines such as psilocybin demonstrate promising nontraditional pharmacological profiles for treating psychiatric syndromes. Structural modifications yield functional selectivity at 5-HT receptors, mitigating hallucinogenic risk while preserving therapeutic efficacy. This study integrates receptor and behavioral data to support ...
Unknown journal
2025-08-14
Kargbo RB.
Europe PMC Published
psilocybin DepressionReceptor PharmacologySafety Other
ImportancePsilocybin-assisted psychotherapy may offer a novel approach to treating depression, anxiety, and existential distress in individuals with life threatening illnesses, where current treatments show limited efficacy.ObjectiveTo evaluate the efficacy and safety of psilocybin-assisted psychotherapy versus active placebo and psychotherapy in adults with...
Unknown journal
2025-08-11
Ross ML, Iyer R, Williams ML, Boughey M, O'Callaghan C, Hiscock R, Dwyer J.
Europe PMC Published
psilocybin DepressionAnxietyEnd-of-Life DistressWellbeingSpiritualityMystical ExperienceClinical TrialRandomized Controlled TrialAdolescentsSafetyAdverse Events Randomized Controlled Trial HumansCritical Illness
Psychedelics, derived from the Greek words "psyche" (soul) and "deloun" (revealing), are substances historically and currently considered "soul-revealing". Also termed hallucinogens due to their impact on sensory perception, they are further categorized into hallucinogens, such as lysergic acid diethylamide (LSD), psilocybin, and mescaline; entactogens or em...
Unknown journal
2025-08-08
Silczuk A, Madejek RJ, Koweszko T, Mularczyk-Tomczewska P, Adamska E, Gujski M, Szulc A.
Europe PMC Published
psilocybin DepressionPTSDAddictionOCDNeuroplasticityMechanism of ActionClinical TrialReview ArticleSafety Clinical Trial HumansLysergic Acid Diethylamide
Tau protein is essential for the structural stability of neurons, particularly through its role in microtubule assembly and axonal transport. However, when abnormally hyperphosphorylated or cleaved, Tau can aggregate into insoluble forms that disrupt neuronal function, contributing to the pathogenesis of neurodegenerative diseases such as Alzheimer's disease...
Unknown journal
2025-08-06
Rebolledo-Pérez L, Hernández-Bello J, Martínez-Ramos A, Castañeda-Arellano R, Fernández-Quezada D, Sandoval-García F, Aguilar-García IG.
Europe PMC Published
psilocybin AddictionNeuroplasticityMechanism of ActionBiomarkersOxidative StressReview ArticleAnimal StudyToxicityInflammation Review Article AnimalsHumans
IntroductionPsilocybin, a serotonergic psychedelic, has shown therapeutic potential in treating mental health disorders by, amongst the many effects, promoting neuroplasticity and reorganising functional connectivity across cortical and subcortical networks involved in emotion and cognition. Veterans with traumatic brain injuries (TBI) often experience chron...
Unknown journal
2025-08-05
Blest-Hopley G, Pasculli G, Ruffell SGD, Tsang W, Emmanuel O, Pate KM, Kettner H, Roseman L, Erritzoe D, Carhart-Harris R.
Europe PMC Published
psilocybin DepressionPTSDNeuroplasticityBrain ImagingEmotional ProcessingVeterans Other
Microdosing psychedelics, the regular use of low doses of LSD or psilocybin, have attracted growing public and scientific interest. This review synthesizes findings from 57 human studies on psychological and physiological outcomes in clinical and non-clinical populations. Reported benefits include improved mood, enhanced cognition, social functioning, and me...
Unknown journal
2025-08-05
Totomanova I, Haijen ECHM, Hurks PPM, Ramaekers JG, Kuypers KPC.
Europe PMC Published
psilocybin AnxietyMicrodosingReview ArticleObservational StudySafety Review Article HumansLysergic Acid Diethylamide
Psilocybin, a compound found in Psilocybe mushrooms, is emerging as a promising treatment for neurodegenerative and psychiatric disorders, including major depressive disorder. Its potential therapeutic effects stem from promoting neuroprotection, neurogenesis, and neuroplasticity, key factors in brain health. Psilocybin could help combat mild neurodegenerati...
Unknown journal
2025-08-04
Adeyinka D, Forsyth D, Currie S, Faraone N.
Europe PMC Published
psilocybin DepressionAddictionNeuroplasticityNeurogenesisPharmacologyMechanism of ActionAgingAnimal StudySafetyDrug Interactions Other
BackgroundPsilocybin-assisted therapy (PAT) has shown promising effects in treating depressive symptoms, but the role of the therapeutic component remains unclear. While most research has focused on the pharmacological effects of psilocybin, the contribution of therapy has been largely overlooked.ObjectiveThis meta-analysis investigated whether the amount of...
Unknown journal
2025-08-04
Hultgren J, Hafsteinsson MH, Brulin JG.
Europe PMC Published
psilocybin DepressionMeta-Analysis Meta-Analysis HumansHallucinogens
Interest in and use of hallucinogens appears to be growing in the United States, yet less is known about the use of multiple hallucinogens. The aims of this study are to characterize subgroups of lifetime hallucinogen use and to identify sociodemographic correlates of these subgroups. Latent class models were fit using 2021-2022 National Survey on Drug Use a...
Unknown journal
2025-08-03
Meacham MC, Mian MN, Wang RC, Coker AR, Anderson BT, Montoy JCC.
Europe PMC Published
psilocybin Clinical TrialObservational Study Clinical Trial
Depression prevalence is markedly elevated in oncological patients, particularly among head and neck cancer (HNC) cohorts, who face twice the prevalence of major depressive disorder (MDD) compared to other cancer populations. MDD in this context independently predicts poorer clinical outcomes and increased morbidity. HNC management often involves acute surgi...
Unknown journal
2025-08-03
Małgorzata W, Kopczyk R, Gerlach A, Rymaszewska J.
Europe PMC Published
psilocybinpsilocin DepressionPTSDMechanism of ActionReceptor PharmacologyClinical TrialObservational StudyCancer PatientsTreatment-Resistant Depression Clinical Trial